Alternatives to TRT: Enclomiphene, hCG, lifestyle, and fertility-preserving options

Alternatives to TRT do exist, and in men with persistent symptoms plus morning total testosterone below 350 ng/dL or free testosterone below 100 pg/mL, Enclomiphene can raise testosterone without shutting down sperm production. The key is matching treatment to the cause. Men with secondary or functional hypogonadism often have options that preserve fertility, maintain testicular function, and may not require lifelong hormone replacement.

Key takeaways

• Male hypogonadism is a clinical syndrome that requires persistent symptoms plus biochemical evidence, not a lab number alone. At Veedma, practical decision thresholds are total testosterone below 350 ng/dL or free testosterone below 100 pg/mL, measured in a morning draw from 07:00 to 11:00 with LH and FSH checked at the same time.^[2]
• TRT suppresses pituitary gonadotropins, meaning LH and FSH, and this suppresses spermatogenesis. According to the Endocrine Society guideline, testosterone therapy is contraindicated in men planning fertility treatment.^[1]
• Enclomiphene is first line for secondary and functional hypogonadism when LH is low or inappropriately normal, especially below 8 mIU/mL, because it raises testosterone through the body’s own signaling pathway and usually preserves testicular size and sperm production.^{[2] [3]}
• Gonadotropin therapy with hCG usually uses 1,000 to 2,000 IU three times weekly. When paternity is the goal, hCG is typically combined with FSH at 75 to 150 IU three times weekly because combined gonadotropin therapy produces better fertility outcomes than hCG alone.
• Lifestyle treatment can improve functional hypogonadism, but average testosterone gains from weight loss alone are often only 1 to 2 nmol/L, which is modest and difficult to sustain long term.^[2]
• The TRAVERSE trial followed 5,246 men for a mean of 33 months and found TRT was noninferior to placebo for major cardiovascular events, but that does not change its fertility suppressing effect or the need for hematocrit monitoring.^[5]

Why alternatives to TRT matter

Alternatives matter because exogenous testosterone suppresses LH, FSH, and sperm production, which makes TRT inappropriate for men who want to preserve fertility.^[1]

TRT is effective for the right patient, but it is not a neutral starting point. Gonadotropins are the pituitary hormones LH and FSH that tell the testes to make testosterone and sperm. When testosterone is given from outside the body, the brain reduces those signals through negative feedback. The result is lower intratesticular testosterone, reduced spermatogenesis, and often testicular atrophy.^{[1] [2]}

That is why any man who may want children, now or later, needs a fertility conversation before treatment starts. According to the Endocrine Society guideline, testosterone therapy is contraindicated in men planning fertility treatment.^[1] This point is routinely missed when men are treated from a total testosterone number alone.

Alternatives also matter because not every case of low testosterone is permanent. Functional hypogonadism means testosterone is low because the hypothalamic pituitary gonadal axis is suppressed by reversible factors such as obesity, metabolic disease, medications, or systemic illness, rather than by irreversible testicular failure. In that setting, replacing testosterone for life may be unnecessary if the underlying problem can be corrected or if the axis can be stimulated instead.^[2]

Before choosing any therapy, the diagnosis still has to be made correctly. Low testosterone is a syndrome, not a lab result. It requires persistent symptoms plus biochemical evidence, ideally with a morning draw and direct free testosterone measurement. LH and FSH must be measured alongside testosterone, because without them you cannot distinguish primary from secondary hypogonadism and you cannot choose the right treatment path. For a full explanation of that distinction, see Primary vs secondary hypogonadism, and for the testing workflow, see The complete low testosterone testing guide.^[2]

The goal is not to avoid TRT because of outdated myths. The TRAVERSE trial, the largest randomized study of TRT, showed no excess major cardiovascular events versus placebo over a mean 33 month follow up in appropriately selected hypogonadal men.^[5] The reason to consider alternatives is simpler and more important. If the testes can still respond, fertility preserving treatment may control symptoms without shutting down the reproductive axis.

How Enclomiphene works for secondary and functional hypogonadism

Enclomiphene can raise endogenous testosterone only when the HPG axis is intact, which makes it a treatment for secondary and functional hypogonadism, not primary testicular failure.^{[2] [3]}

The HPG axis is the hypothalamus, pituitary, and gonadal signaling system that controls testosterone production. Enclomiphene is the trans isomer of clomiphene citrate, isolated so that men receive the anti estrogenic component without the prolonged estrogenic effects of zuclomiphene, the cis isomer. Mechanistically, Enclomiphene blocks estrogen receptors at the hypothalamus. That reduces estrogen mediated negative feedback, increases GnRH output, raises pituitary LH and FSH, and tells the testes to produce testosterone naturally.^[2]

This mechanism explains why Enclomiphene for low testosterone is such an important alternative to TRT in secondary and functional disease. Instead of replacing testosterone from the outside, it restores the signaling pathway. That means the testes keep working, intratesticular testosterone is maintained, and spermatogenesis is usually preserved. In practice, this is most relevant when LH is low or normal, especially below 8 mIU/mL, which suggests the testes are still capable of responding.

A 2014 BJU International trial found that Enclomiphene increased serum testosterone while preserving sperm counts, whereas topical testosterone lowered sperm concentration in men with secondary hypogonadism.^[3] That difference is clinically decisive for men in their reproductive years. It also matters for men who are not trying to conceive today but do not want to close that option later.

Enclomiphene has other practical advantages. It maintains testicular size and function rather than causing atrophy. It works with physiologic regulation, so testosterone rises through a normal endocrine pathway rather than through supraphysiologic peaks. It may also be easier to discontinue if the underlying driver of functional hypogonadism improves. This is why Enclomiphene combined with lifestyle modification is often the most rational first step for obesity related or medication related suppression of the axis.

In the U.S., Enclomiphene is typically accessed through compounding pharmacies and specialized men’s health clinics. It remains an off label treatment, and it is not FDA approved as a standalone product for hypogonadism. That regulatory status does not negate its clinical usefulness, but it does mean treatment should be guided by licensed providers who understand the diagnostic requirements and monitoring needs.

Enclomiphene versus TRT

Enclomiphene and TRT treat low testosterone in fundamentally different ways.^{[1] [2] [3]}

For a deeper review of the signaling pathway behind this difference, see How the HPG axis works.

How Enclomiphene compares with other SERMs

Among SERMs, Enclomiphene is distinguished by being the purified trans isomer that drives the testosterone response while avoiding prolonged estrogenic exposure from zuclomiphene, the cis isomer.^{[2] [3]}

SERM means selective estrogen receptor modulator. In men with secondary or functional hypogonadism, these drugs work by reducing estrogen mediated negative feedback at the hypothalamus and pituitary, which can raise GnRH, LH, FSH, and endogenous testosterone. Enclomiphene has the most direct mechanistic rationale in this setting because it isolates the anti estrogenic trans isomer and avoids the zuclomiphene related estrogenic effects that can contribute to mood changes, visual symptoms, and gynecomastia in some men.

According to the European Association of Urology guidance, SERMs are off label options to restore testosterone levels and fertility in men with functional secondary hypogonadism.^[2] That category includes Enclomiphene, tamoxifen, and raloxifene. Compared with those alternatives, Enclomiphene is generally the most targeted option for male hypogonadism because it is designed around the isomer that increases gonadotropin signaling without carrying along the less favorable cis isomer.

Other SERMs are less studied for male hypogonadism and are usually not first choice in current U.S. practice. There is also a class wide concern about venous thromboembolism risk with SERMs, which means treatment still requires clinical judgment and follow up.^[2]

The practical takeaway is straightforward. If a man has secondary or functional hypogonadism and wants an alternative to TRT, Enclomiphene is usually the preferred SERM. If he has primary hypogonadism, no SERM will fix a testis that cannot respond to LH.

Other fertility-preserving and non TRT options

hCG and FSH can stimulate the testes directly and are the basis of the most established hCG based fertility preserving treatment when conception is an immediate goal.

How gonadotropin therapy with hCG fits

Gonadotropin therapy with hCG works by mimicking LH at the testis.

hCG, human chorionic gonadotropin, activates LH receptors on Leydig cells and drives intratesticular testosterone production. Typical dosing is 1,000 to 2,000 IU three times weekly. When paternity is the goal, hCG is typically combined with FSH at 75 to 150 IU three times weekly because combined gonadotropin therapy produces better fertility outcomes than hCG alone. FSH stimulates Sertoli cell function and spermatogenesis more directly. The AUA and ASRM infertility guideline supports gonadotropin based treatment in this setting, and guidance consistently favors combining hCG with FSH when the goal is paternity rather than symptom control alone.

This approach is effective, but it is also more burdensome than Enclomiphene. It usually means injections, a more fertility focused protocol, and closer coordination with semen analysis. For men who want to preserve fertility but are not trying to conceive immediately, Enclomiphene is often the preferred alternative because it is oral, preserves the axis, and may be simpler to manage.

Aromatase inhibitors

Aromatase inhibitors can increase gonadotropin signaling in selected men, but the evidence base is weaker and long term use can compromise bone health.^[2]

Aromatase is the enzyme that converts testosterone to estradiol. In men with obesity and metabolic dysfunction, aromatase activity is often increased because adipose tissue expresses the enzyme. Letrozole, anastrozole, and exemestane reduce that conversion, which can lower estradiol feedback on the hypothalamus and pituitary and allow testosterone to rise. This requires an intact HPG axis, so these drugs are not useful in primary hypogonadism.

The limitation is evidence quality. According to EAU guidance, the data are poor for routine use, and prolonged estrogen suppression can reduce bone density and increase osteoporosis risk.^[2] That makes aromatase inhibitors a niche option rather than a preferred first line treatment.

Lifestyle and root cause treatment

Lifestyle change is first line treatment for functional hypogonadism, but weight loss alone usually raises testosterone by only about 1 to 2 nmol/L and the effect is hard to sustain.^[2]

Functional hypogonadism is low testosterone caused by reversible suppression of the HPG axis rather than structural failure of the testes or pituitary. Obesity is the commonest real world driver. A low calorie diet can improve obesity associated secondary hypogonadism, and physical activity can raise testosterone in proportion to exercise volume and weight loss achieved.^[2] That is why guidelines strongly recommend weight reduction, medication review, and treatment of comorbidities before jumping to testosterone replacement.

The problem is magnitude and durability. The average hormonal gain from lifestyle alone is modest. Long term durability is also poor, with 60 to 86 percent of lost weight commonly regained within 3 years. Many symptomatic men still remain below treatment thresholds, which is one reason the simple advice to “lose weight first” often fails in practice. Men with low testosterone frequently struggle with reduced energy, increased fat mass, and poorer training response, which makes lifestyle change harder precisely when they need it most.

Why combination treatment is more realistic

Combination therapy often works better than lifestyle alone because hormonal recovery can make the lifestyle plan more achievable.^[4]

The T4DM randomized trial showed that testosterone plus a structured lifestyle program outperformed lifestyle intervention alone over two years in men with impaired glucose regulation and low testosterone.^[4] The most important lesson is practical rather than ideological. Men often need some hormonal support before they can train effectively, recover well, and sustain meaningful body composition change.

In men with secondary or functional hypogonadism, Enclomiphene plus lifestyle modification is the logical version of this strategy. It addresses the hormonal deficit while keeping the reproductive axis active. If the underlying condition improves, treatment may later be reduced or stopped without the added complication of a suppressed axis.

Treat the cause before replacing the hormone

Specific reversible causes of hypogonadism should be treated directly because hormone normalization may follow if the driver is removed.^{[1] [2]}

Pituitary prolactinomas often respond to dopamine agonists and may fully restore testosterone production once prolactin is controlled. Hyperprolactinemia means an abnormally high prolactin level. When the cause is a medication, such as a dopamine blocking drug, changing the medication can reverse the endocrine suppression. Iron overload, or hemochromatosis, may improve with phlebotomy, which is scheduled blood removal. Drug induced hypogonadism should prompt a review of opioids, exogenous steroids, finasteride, and other suppressive agents whenever clinically feasible.^{[1] [2]}

This is why a complete workup matters. A man with a reversible endocrine problem should not be pushed prematurely into lifelong replacement therapy. For the framework used to sort reversible from irreversible causes, see Functional vs organic hypogonadism.

Supplements and natural testosterone treatment

Correcting zinc, vitamin D, or magnesium deficiency can modestly support testosterone physiology, but no supplement is a substitute for treating clinical hypogonadism.

That distinction matters. Correcting a deficiency is evidence based medicine. Supplementing an already adequate level is different, and the expected effect is usually small or absent. NIH Office of Dietary Supplements fact sheets note that zinc, vitamin D, and magnesium are essential for normal physiology, but none is presented as a stand alone treatment for confirmed male hypogonadism.

• Zinc correction may help men who are truly zinc deficient, especially when dietary intake is poor.
• Vitamin D replacement is appropriate when 25 hydroxyvitamin D is low, and men often report better overall energy after deficiency is corrected, but this is not the same as treating hypogonadism.
• Magnesium repletion may support general metabolic and neuromuscular function in deficient men, but it is not a direct testosterone therapy.

Botanical products such as ashwagandha, tongkat ali, and fenugreek have limited evidence for small short term changes, usually in men with stress, poor sleep, or borderline nutritional status rather than documented hypogonadism. Online “testosterone boosters” are even less reliable. Most are unproven, under regulated, or both.

For men with persistent symptoms and confirmed biochemical deficiency, supplements are adjuncts at most. They do not replace Enclomiphene for low testosterone when the problem is secondary or functional hypogonadism, and they do not replace TRT when the problem is primary testicular failure.

Myth vs fact

Myth: TRT preserves fertility if testosterone levels look normal

Fact: TRT suppresses LH and FSH, which lowers intratesticular testosterone and suppresses spermatogenesis. According to the Endocrine Society guideline, testosterone therapy is contraindicated in men planning fertility treatment.^[1]

Myth: Enclomiphene works for every man with low testosterone

Fact: Enclomiphene requires an intact HPG axis. It is appropriate for secondary and functional hypogonadism, not for primary hypogonadism with high LH and low testosterone, or for severe organic pituitary disease where the signaling pathway cannot respond normally.^{[2] [3]}

Myth: Gonadotropin therapy with hCG and Enclomiphene are the same thing

Fact: Both can preserve fertility, but they act at different points in the axis. hCG directly mimics LH at the testis, and when paternity is the goal, hCG is typically combined with FSH. Enclomiphene works upstream at the hypothalamus and pituitary and is often preferred when immediate fertility treatment is not required. ^[2]

Myth: Clomiphene for men and Enclomiphene are interchangeable

Fact: Traditional clomiphene citrate contains both enclomiphene and zuclomiphene. Enclomiphene isolates the trans isomer that raises testosterone, while avoiding the cis isomer that is more likely to cause estrogenic side effects such as mood changes, visual symptoms, and gynecomastia.^{[2] [3]}

Myth: Natural testosterone treatment means boosters can replace medical care

Fact: Correcting zinc, vitamin D, or magnesium deficiency can help general health, but no over the counter supplement replaces a diagnostic workup or evidence based treatment for clinical hypogonadism.

Bottom line

The best alternative to TRT depends on why testosterone is low. For men with secondary or functional hypogonadism, Enclomiphene is usually the leading option because it raises testosterone through the body’s own signaling pathway while preserving fertility, whereas hCG with or without FSH is more appropriate when immediate conception is the main goal. For the full diagnostic and treatment roadmap, see the Low testosterone hub.

Veedma offers a thorough diagnostic workup with an advanced lab panel that measures Total Testosterone by LC MS/MS and Free Testosterone by Equilibrium Dialysis with LC MS/MS, alongside LH, FSH, estradiol, CBC, Comprehensive Metabolic Panel, vitamin D, PSA for men age 40 and older, insulin when BMI is above 25, and prolactin, TSH, and a lipid panel as clinically indicated, or a review of existing lab results including uploads from Function Health. Across the U.S., licensed providers create individualized treatment plans with Enclomiphene as first line for eligible men, or the Enclomiphene plus Tadalafil combination tablet when erection or urinary symptoms are also present, then monitor response after the first month and every 6 months with protocol adjustments as needed.

References

1. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. The Journal of clinical endocrinology and metabolism. 2018;103:1715-1744. PMID: 29562364
2. Salonia A, Capogrosso P, Boeri L, et al. European Association of Urology Guidelines on Male Sexual and Reproductive Health: 2025 Update on Male Hypogonadism, Erectile Dysfunction, Premature Ejaculation, and Peyronie’s Disease. European urology. 2025;88:76-102. PMID: 40340108
3. Rahnema CD, Lipshultz LI, Crosnoe LE, et al. Anabolic steroid-induced hypogonadism: diagnosis and treatment. Fertility and sterility. 2014;101:1271-9. PMID: 24636400
4. Wittert G, Umapathysivam MM. Testosterone and the prevention of type 2 diabetes mellitus: therapeutic implications from recent trials. Current opinion in endocrinology, diabetes, and obesity. 2024;31:243-248. PMID: 39285839
5. Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular Safety of Testosterone-Replacement Therapy. The New England journal of medicine. 2023;389:107-117. PMID: 37326322